1.	Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PX-171-009, NCT01080391
2.	A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PX-171-011, NCT01302392
3.	Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: PX-171-007, NCT00531284
4.	Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: UMCC 2009.056, HUM30396, NCT01029054
5.	Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma Phase: Phase II Type: Treatment Status: Closed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: PX-171-003, NCT00511238
6.	Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PX-171-005, NCT00721734
7.	Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PX-171-004, NCT00530816
8.	Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 10-228, NCT01351623
9.	Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 11-279, NCT01470196
10.	Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies Phase: Phase I Type: Treatment Status: Completed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: PX-171-002, NCT00150462
11.	Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PX-171-006, NCT00603447
12.	Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease Phase: No phase specified Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 2011-002, NCT01410500